Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Disrupt PAD BTK II Study With the Shockwave Peripheral IVL System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05007925
Recruitment Status : Enrolling by invitation
First Posted : August 17, 2021
Last Update Posted : July 28, 2022
Sponsor:
Information provided by (Responsible Party):
Shockwave Medical, Inc.

Tracking Information
First Submitted Date  ICMJE August 9, 2021
First Posted Date  ICMJE August 17, 2021
Last Update Posted Date July 28, 2022
Actual Study Start Date  ICMJE November 18, 2021
Estimated Primary Completion Date November 23, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 9, 2021)
  • Procedure Success [ Time Frame: At procedure ]
    Procedure Success defined as ≤50% residual stenosis for all treated target lesions without serious angiographic complications (flow-limiting dissection, perforation, distal embolization, or acute vessel closure) as assessed by the angiographic core lab
  • Major Adverse Limb Events (MALE) + Post-Operative Death (POD) [ Time Frame: 30 days ]
    Major Adverse Limb Events (MALE) + Post-Operative Death (POD) at 30 days defined as a composite of:
    • all-cause death
    • above-ankle amputation of the index limb
    • major reintervention (new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis) of the index limb involving a BTK artery
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 9, 2021)
  • Serious angiographic complications [ Time Frame: At procedure ]
    Serious angiographic complications (flow-limiting dissection, perforation, distal embolization, or acute vessel closure) as assessed by the angiographic core lab
  • Lesion Success [ Time Frame: At procedure ]
    Lesion Success defined as final residual stenosis ≤50% in the target lesion without significant angiographic complications as assessed by the angiographic core lab
  • Primary Patency [ Time Frame: 6 and 12 months ]
    Primary Patency at 6 and 12 months defined as the absence of both total occlusion (100% diameter stenosis by DUS) in all of the target lesions in a flow pathway, as well as a Clinically-Driven Target Lesion Revascularization (CD-TLR)
  • Clinically Relevant Target Lesion Failure (CR-TLF) [ Time Frame: 30 days, 6, 12 & 24 months ]
    Clinically Relevant Target Lesion Failure (CR-TLF) at 30 days, 6, 12 & 24 months defined as a composite of:
    • CD-TLR
    • Ischemia-related major amputation
    • Clinically relevant target lesion occlusion
  • Major Adverse Events (MAE) [ Time Frame: 30 days ]
    Major Adverse Events (MAE) at 30 days defined as a composite of:
    • Need for emergency surgical revascularization of target limb
    • Unplanned target limb major amputation (above the ankle)
    • Symptomatic thrombus or distal emboli that require surgical, mechanical, or pharmacologic means to improve flow, and extend hospitalization
    • Perforations that require an intervention, including bail-out stenting
  • VascuQoL [ Time Frame: 30 days, 6, 12 & 24 months ]
    Quality of Life (QoL) assessed by VascuQoL questionnaire at 30 days, 6, 12 & 24 months, reported as change from baseline
  • Ankle-brachial index (ABI) or toe-brachial index (TBI) [ Time Frame: 30 days, 6, 12 & 24 months ]
    Ankle-brachial index (ABI) or toe-brachial index (TBI) at 30 days, 6, 12 & 24 months, reported as change from baseline
  • Rutherford Category [ Time Frame: 30 days, 6, 12 & 24 months ]
    Rutherford Category at 30 days, 6, 12 & 24 months, reported as change from baseline
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Disrupt PAD BTK II Study With the Shockwave Peripheral IVL System
Official Title  ICMJE Prospective, Multi-center, Single-arm Study of the Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System for Treatment of Calcified Peripheral Arterial Disease (PAD) in Below-the-Knee (BTK) Arteries
Brief Summary

To assess the continued safety, effectiveness, and optimal clinical use of the Shockwave Medical Peripheral IVL System for the treatment of calcified, stenotic BTK arteries.

Post-market, prospective , multi-center, single-arm study.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Peripheral Artery Disease
Intervention  ICMJE Device: Intravascular Lithotripsy
Localized peripheral intravascular lithotripsy
Study Arms  ICMJE Experimental: Single-arm
Intervention: Device: Intravascular Lithotripsy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Enrolling by invitation
Estimated Enrollment  ICMJE
 (submitted: August 9, 2021)
250
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE October 15, 2025
Estimated Primary Completion Date November 23, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

- General Inclusion Criteria

  1. Age of subject is ≥ 18.
  2. Subject is able and willing to comply with all assessments in the study.
  3. Subject or subject's legal representative has been informed of the nature of the study, agrees to participate, and has signed the approved consent form.
  4. Critical limb ischemia (CLI) in the target limb from the distal segment (P3) of the popliteal artery to the ankle joint prior to the study procedure with Rutherford Category 4-5; or Rutherford 3 in the target limb from the distal segment (P3) of the popliteal artery to the ankle joint prior to the study procedure.
  5. Estimated life expectancy >1 year.

    • Angiographic Inclusion Criteria
  6. Up to 2 below-the-knee target lesion(s) in native vessels in one or both limbs.
  7. Target lesion reference vessel diameter (RVD) between 2.0 mm and 4.0 mm by investigator visual estimate.
  8. Target lesion with ≥70% stenosis by investigator visual estimate.
  9. Target lesion length is ≤200 mm by investigator visual estimate. Target lesion can be all or part of the 200 mm treated zone.
  10. Distal reconstitution of at least one pedal vessel (<50% stenosis) (desert foot excluded).
  11. Evidence of at least moderate calcification at the target lesion site by angiography/IVUS OR non-dilatable lesion indicating presence of calcium. Must meet one of the following:

    1. Angiography requires fluoroscopic evidence of calcification on parallel sides of the vessel and extending > 50% the length of the lesion.
    2. IVUS requires presence of ≥270 degrees of calcium over the course of at least 10mm.
    3. Non-dilatable lesion requires attempted treatment with PTA during the index procedure with residual stenosis > 50% and no serious angiographic complications.

Exclusion Criteria:

- General Exclusion Criteria

  1. Rutherford Category 0, 1, 2 or 6 (target limb).
  2. Osteomyelitis or deep soft tissue infection extending proximal from the metatarsals that cannot be treated with an individual toe ray amputation or transmetatarsal amputation (TMA) .
  3. History of endovascular or surgical procedure on the target limb within the last 30 days, or planned within 30 days of the index procedure.
  4. Subject in whom antiplatelet or anticoagulant therapy is contraindicated.
  5. Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.
  6. Subject has known allergy to urethane, nylon, or silicone.
  7. Myocardial infarction within 30 days prior to enrollment.
  8. History of stroke within 60 days prior to enrollment.
  9. Subject has acute or chronic renal disease with eGFR <30 ml/min/1.73 m2 (using CKD-EPI formula), unless on renal replacement therapy.
  10. Subject is pregnant or nursing.
  11. Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.
  12. Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.
  13. Covid-19 diagnosis within 90 days.
  14. The planned use of cutting/scoring balloons, re-entry or atherectomy devices in target lesions during the index procedure.
  15. Planned major amputation (of either leg).
  16. Acute limb ischemia.
  17. Occlusion of all the inframalleolar outflow arteries/vessels (i.e., desert foot).
  18. Subject has an anticipated life span of less than one (1) year.
  19. Subject already enrolled into this study.

    • Angiographic Exclusion Criteria
  20. Failure to treat clinically significant inflow lesions in the ipsilateral iliac, femoral, or popliteal arteries with ≤30% residual stenosis, and no serious angiographic complications (e.g., embolism).
  21. Failure to successfully treat significant non-target infra-popliteal lesions prior to treatment of target lesion(s). Successful treatment is defined as obtaining ≤50% residual stenosis with no serious angiographic complications (e.g., embolism ).
  22. Failed PTA in target lesion during index procedure with angiographic evidence of serious angiographic complications .
  23. Target lesion includes in-stent restenosis.
  24. Evidence of aneurysm or thrombus in target vessel.
  25. No calcium or mild calcium in the target lesion.
  26. Target lesion within native or synthetic vessel grafts.
  27. Failure to successfully cross the guidewire across the target lesion; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Germany,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05007925
Other Study ID Numbers  ICMJE CP 65007
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Shockwave Medical, Inc.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Shockwave Medical, Inc.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Shockwave Medical, Inc.
Verification Date February 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP